AzTrials
AzTrials

Ondine SyndromeOndineCoNCT06337149

Relationship Between Breathing and Attention in Children With Ondine Syndrome

An observational study of Ondine Syndrome and Congenital Central Hypoventilation Syndrome (CCHS), run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Congenital central hypoventilation syndrome (CCHS) is a rare disorder of autonomic and respiratory regulation that alters oxygen delivery to the brain. CCHS patients are at risk for broad neurocognitive deficits. Read more about this study

Who is it for?
Ages 6 to 16 years
What is being tested?
neuropsychological tests used usually in clinical practice (TEA-ch, NEPSY, BRIEF) and research (Conners 3, K-CPT II or CPT III, Flankers Task)
How many people
20 participants
Where
1 siteFrance
Study dates
29 Feb 2024to 1 Sep 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 16 years
  • All sexes
  • No healthy volunteers
  • Child

Study population: Ondine Syndrome, children with CCHS

Who may be able to join

  • children with CCHS (Ondine Syndrome) and IQ > 70, age from 6 to 16 years old, french speaking, informed consent signed by both parents and oral agreement in principle given by the subject.

Who cannot join

  • IQ < 70

Trial locations and contacts

1 site in 1 country.

Christophe DELCLAUX, MD, PhD contact

+331 40 03 41 90

christophe.delclaux@aphp.fr

Benjamin DUDOIGNON, MD contact

+331 40 03 41 90

benjamin.dudoignon@aphp.fr

France1 site, 1 recruiting
  • Robert Debre Hospital

    Paris, 75019

    Christophe DELCLAUX, MD, PhD, +331 40 03 41 90, christophe.delclaux@aphp.fr

    Benjamin DUDOIGNON, MD, +331 40 03 41 90, benjamin.dudoignon@aphp.fr

    Recruiting

Other trials in France

About this study

Congenital central hypoventilation syndrome (CCHS) is a rare disorder of autonomic and respiratory regulation that alters oxygen delivery to the brain. CCHS patients are at risk for broad neurocognitive deficits. Patients retain ventilatory activity when awake through a respiratory-related cortical network but the need to mobilise cortical resources to breathe lead to breathing-cognition interferences during cognitive tasks. The purpose of this study is to assess the relationship between breathing pattern and attention in CCHS children

Read the detailed description

Congenital central hypoventilation syndrome (CCHS) is a rare genetic disorder caused by PHOX2B gene mutations. CCHS is characterized by hypoventilation and autonomic nervous system dysregulation and global dysautonomia necessitating artificial ventilation. CCHS increases the risk to develop neurocognitive deficiencies. Patients retain ventilatory activity when awake through a respiratory-related cortical network but the need to mobilise cortical resources to breathe lead to breathing-cognition interferences during cognitive tasks.

No study has focused on attentional abilities in CCHS pediatric population to highlight a specific attentional profile or to investigate the double task paradigm impact when attentional resources and management of spontaneous breathing are competing.

The aim of this study is to (i) Understand the link between spontaneous breathing and attentional functioning in CCHS children by comparing the evolution of breathing pattern relatively to the complexity of the attentionals tasks.

(ii) Characterize the attentional profil of CCHS patients by comparing attentional tasks performance of CCHS children versus control children (iii) Measure the impact of variables such as age and CO2 ventilatory response on attentional performances, by comparing attentional performances of the young patient group (< 50e p) to the attentional performances of older patient group (> 50e p) and studying the correlation between ventilatory response to CO2 and attentional performance (iv) Investigate the link between clinicals and behavioural tools regarding attentional and executive domains by studying the correlation between the cognitif test and inventories results Hypothese : attentional task could be link to a deficit in breathing function leading to hypoxemia and hypercapnia (alveolar hypoventilation).

Methode : compare CCHS patients performances and control group in neuropsychological tests used usually in clinical practice (TEA-ch, NEPSY, BRIEF) and research (Conners 3, K-CPT II or CPT III, Flankers Task).

Twenty children (age range : 6 to 16 years old) with CCHS and IQ > 70 and twenty control subjects in the same age range without neurodevelopmental disorder diagnosis will be enrolled.

Firstly, subjects of both groups will respond to a neuropsychological assessment including intellectual Wechsler scale (WISC V), instruction comprehension test (Nepsy II), a manual laterality test and attentional and executive assessment (TEA-ch + NEPSY II).

Secondarily, CCHS group assessment will be completed with a double task paradigm. Our protocol includes a simple task condition (the patient must remain still) and a double task condition (the patient respond to the flanker tasks and K-CPT II or CPT III).

Procedure : continuous recording of breathing parameters : oxygen saturation, exhaled PCO2 (PETCO2 with nasal cannula) and respiratory rate. Breathing respiratory parameters will be recorded during simple condition and double task condition. "

Being tested
neuropsychological tests used usually in clinical practice (TEA-ch, NEPSY, BRIEF) and research (Conners 3, K-CPT II or CPT III, Flankers Task)
Medical subject headings
Sleep Apnea, Central, Congenital central hypoventilation syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • neuropsychological tests used usually in clinical practice (TEA-ch, NEPSY, BRIEF) and research (Conners 3, K-CPT II or CPT III, Flankers Task)Other

    neuropsychological tests used usually in clinical practice (TEA-ch, NEPSY, BRIEF) and research (Conners 3, K-CPT II or CPT III, Flankers Task)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Wechsler scale

    Neuropsychological assessement

    Measured: 12 months

  2. Nepsy II test

    Neuropsychological assessement

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Mar 2024
  2. Study start29 Feb 2024
  3. Primary completion1 Mar 2025 (estimated)
  4. Study completion1 Sep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06337149
Sponsor's protocol ID
APHP230348
Other IDs
IDRCB: 2023-A00006-39
Acronym
OndineCo
Status last verified
Mar 2024
First submitted
22 Mar 2024
Last updated
29 Mar 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Ondine Syndrome and Congenital Central Hypoventilation Syndrome (CCHS), run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Christophe DELCLAUX, MD, PhD (+331 40 03 41 90, christophe.delclaux@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Wechsler scale (time frame: 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in